Investigation of optimal regimen of Fulvestrant in patients with postmenopausal ER-positive advanced recurrent breast cancer
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 12 Sep 2017 Results of subanalysis assessing factors associated with prolonged time to treatment failure with fulvestrant 500mg in patients with postmenopausal estrogen receptor-positive advanced/metastatic breast cancer, were presented at the 42nd European Society for Medical Oncology Congress.
- 17 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 14 Jan 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.